C9307 Linvoseltamab-gcpt - CanMED: HCPCS

Return Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Linvoseltamab-gcpt

Brand Name:

Lynozyfic

Strength:

1mg

HCPCS:

C9307

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

BCMA, CD3

Oral (Y/N):

No

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

Jan. 12, 2026

CMS Discontinuation Date:

March 18, 2026

Status:

In Use